Sector News

Advent, Baxter preparing bids for India's Gland Pharma: sources

April 18, 2016
Life sciences

Global buyout firm Advent International and U.S.-based Baxter International (BAX.N) are among suitors preparing to submit separate bids to buy unlisted Indian drugmaker Gland Pharma Ltd, three people with direct knowledge of the matter told Reuters.

A deal would underscore the positive outlook for drugmakers in India, which is a major supplier to the world and counts the United States as its largest export market thanks to lower manufacturing and labor costs.

Indian drugmakers are among the world’s biggest producers of cheap generic medicines, as developed nations battle rising healthcare costs and big-selling drugs going off-patent in the lucrative U.S. market.

Overseas drugmakers as well as private equity firms such as KKR & Co and Singapore’s state investment firm Temasek Holdings have invested in the Indian companies in the recent past to cash in on growing demand for cheaper drugs overseas.

Gland Pharma founders and KKR, who jointly own about 96 percent of the company, are selling their combined stake, which is valued at between $1 billion and $1.5 billion, the people said.

Indian drugmaker Torrent Pharmaceuticals is the other company set to place binding bids due by middle of next month, said the people, who declined to be identified as the deal talks are confidential.

Advent, KKR and Baxter declined to comment. Officials at Gland and Torrent did not respond to Reuters’ request for comment.

KKR invested about $200 million in Gland Pharma in 2013, at that time the largest private equity investment in the local pharmaceutical sector. The stake size was not disclosed, but sources said the company was valued at about $600 million then.

Gland Pharma, based in the southern India city of Hyderabad, makes injectables – widely-used medicines administered through vials, syringes, bags and pumps, which are harder to manufacture than regular medicines.

A shortage of such injectables in recent years has driven up prices and made it an increasingly lucrative business opportunity for drugmakers, sparking investors’ interest in companies such as Gland Pharma.

Drugs giant Pfizer acquired U.S. firm Hospira for $17 billion last year partly to bolster its injectable drugs business.

Mylan NV paid $1.6 billion to buy the injectable drugs unit of India’s Strides Arcolabs – now known as Strides Shasun STSA.NS – in 2013.

By Sumeet Chatterjee and Prakash Chakravarti

Source: Reuters

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”